Metagenomi Therapeutics, Inc. (MGX)
NASDAQ: MGX · Real-Time Price · USD
1.600
+0.120 (8.11%)
At close: Mar 9, 2026, 4:00 PM EDT
1.610
+0.010 (0.62%)
After-hours: Mar 9, 2026, 7:40 PM EDT
Metagenomi Therapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Net Income | -87.87 | -78.06 | -68.26 | -43.59 | -21.44 |
| Depreciation & Amortization | 5.32 | 5.41 | 4.21 | 1.73 | 0.39 |
| Asset Writedown & Restructuring Costs | 0.5 | 1.04 | 0.02 | 0.28 | - |
| Loss (Gain) From Sale of Investments | -1.71 | 3.02 | -11.34 | -1.22 | -2.56 |
| Stock-Based Compensation | 11.85 | 16.2 | 6.92 | 1.96 | 0.38 |
| Other Operating Activities | 5.11 | 2.98 | 3.47 | 1.08 | 1.24 |
| Change in Accounts Receivable | 0.95 | 1.19 | -1.18 | -1.27 | - |
| Change in Accounts Payable | 1.05 | -1.11 | -0.08 | 0.72 | 0.7 |
| Change in Unearned Revenue | -21.1 | -46.8 | -30.3 | 65.66 | 44.23 |
| Change in Income Taxes | - | -3.27 | 1.73 | 1.54 | - |
| Change in Other Net Operating Assets | -3 | -9.69 | 3.4 | 2.84 | 1.33 |
| Operating Cash Flow | -88.89 | -109.07 | -91.41 | 29.72 | 24.26 |
| Operating Cash Flow Growth | - | - | - | 22.54% | - |
| Capital Expenditures | -0.57 | -3.11 | -9.81 | -13.98 | -2.9 |
| Sale of Property, Plant & Equipment | 0.04 | - | - | - | - |
| Investment in Securities | 104.07 | -85.04 | 55.55 | -108.22 | -71.41 |
| Investing Cash Flow | 103.53 | -88.16 | 45.73 | -122.2 | -74.32 |
| Long-Term Debt Issued | - | - | - | - | 29.97 |
| Net Debt Issued (Repaid) | - | - | - | - | 29.97 |
| Issuance of Common Stock | 0.2 | 84.01 | - | - | - |
| Other Financing Activities | -0.56 | - | -3.28 | - | - |
| Financing Cash Flow | -0.36 | 84.01 | 1.01 | 239.59 | 39.92 |
| Net Cash Flow | 14.28 | -113.22 | -44.66 | 147.12 | -10.14 |
| Free Cash Flow | -89.47 | -112.19 | -101.22 | 15.75 | 21.35 |
| Free Cash Flow Growth | - | - | - | -26.26% | - |
| Free Cash Flow Margin | -354.88% | -214.53% | -226.17% | 91.55% | 8787.65% |
| Free Cash Flow Per Share | -2.40 | -3.40 | -29.73 | 4.63 | 3.75 |
| Cash Interest Paid | - | - | - | 2.16 | 1.45 |
| Cash Income Tax Paid | -2.24 | 3.51 | 2.25 | - | - |
| Levered Free Cash Flow | -53.31 | -73.35 | -31.65 | -19.71 | - |
| Unlevered Free Cash Flow | -53.31 | -73.35 | -31.65 | -19.65 | - |
| Change in Working Capital | -22.09 | -59.67 | -26.43 | 69.49 | 46.26 |
Source: S&P Capital IQ. Standard template.
Financial Sources.